z-logo
Premium
Ampicillin‐ and ampicillin/sulbactam‐resistant Escherichia coli infection in a neonatal intensive care unit in Japan
Author(s) -
Saida Ken,
Ito Yukako,
Shima Yosuke,
Kasuga Eriko,
Kusakari Mai,
Miyosawa Yukihide,
Baba Atsushi
Publication year - 2016
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.12984
Subject(s) - medicine , ampicillin , neonatal intensive care unit , escherichia coli , sulbactam , intensive care unit , incidence (geometry) , microbiology and biotechnology , amp resistance , population , pediatrics , antibiotic resistance , antibiotics , biology , environmental health , biochemistry , physics , optics , imipenem , gene
The incidence of ampicillin (ABPC)‐resistant Escherichia coli ( E . coli ) infection in very low‐birthweight infants has been increasing. The rate of ABPC/sulbactam (ABPC/SBT)‐resistant E . coli in this population, however, is currently unknown. We encountered two cases of severe infection due to resistant E. coli and retrospectively studied the prevalence of ABPC‐ and ABPC/SBT‐resistant E . coli in regular surveillance cultures obtained from all neonatal intensive care unit (NICU) patients between 2000 and 2013. The overall prevalence of ABPC‐resistant E . coli was 39% (47/120), accounting for 63% of cases (32/51) between 2007 and 2013, compared with 22% (15/69) between 2000 and 2006. The prevalence of ABPC/SBT resistance was 17% (20/120), which was similar in both periods (16%, 8/51 vs 17%, 12/69). According to these results, not only ABPC, but also ABPC/SBT‐resistant E . coli must be considered in the NICU.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom